NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced that it has been selected for the Fortune Future 50 list; a ranking celebrating the world’s most forward-looking, innovative companies that are best set up for the future.
Fortune magazine, in partnership with The Boston Consulting Group, ranked Medidata 11th in the Challengers category for the inaugural 2017 Fortune Future 50 list, as a company that is positioned for future growth.
"Every step we’ve taken since our doors opened in 1999 has been about guaranteeing that we don't just facilitate efficient clinical trials today, but solve the problems of the future,” said Mike Capone, chief operating officer at Medidata. “We’ve made our mark by redefining industry standards with data and analytics and more to solve the most challenging problems for life sciences companies. We believe in our employees and technology, together they are creating new possibilities and hope for patients around the world.”
The Fortune Future 50 was featured in a special edition of the publication dedicated to the connective tissue of the modern corporate enterprise – its technology. The list was compiled based on a combination of external market potential and internal capability-based lens. Rankings included five core beliefs; Market: Valuable long-term growth opportunities; Strategy Vitality: patterns of exploratory thinking, strong long-term orientation; Technology & Investments: innovates in emergent tech areas (AI, digital, etc.), makes appropriate investments into organic growth; People: open to diverse sources of management talent, provides leadership opportunities at young age; Structure: tends to be more agile/youthful, track record of sustained growth.
About Medidata
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including more than 850 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.
